Publications by authors named "Inge Haeck"
Introduction And Objectives: Tralokinumab-a biological that specifically targets interleukin-13-is one of the newer advanced systemic treatments for patients with moderate-to-severe atopic dermatitis (AD). Although safety and efficacy have been shown in phase-III clinical trials, daily practice data are needed. Therefore, the aim of this study was to evaluate 28-week safety and effectiveness, serum proteins and total IgE levels in adult AD patients treated with tralokinumab in daily practice.
View Article and Find Full Text PDFArticle Synopsis
- The study examines the long-term effectiveness and safety of dupilumab, a treatment for atopic dermatitis (AD), in a diverse group of patients over a period of up to 5 years.
- Conducted in the Netherlands using the BioDay registry, the research includes 1,286 patients of different age groups receiving dupilumab between 2017 and 2022, with outcomes evaluated using various clinical measures.
- Results show that a majority of patients maintained controlled AD symptoms, with high levels of treatment effectiveness observed over time, and factors for treatment discontinuation were also assessed.
Article Synopsis
- A study evaluated the effectiveness and safety of dupilumab for treating moderate-to-severe atopic dermatitis (AD) over a long-term period of up to 5 years, emphasizing patient-reported outcomes.
- Data from 1223 patients (1108 adults and 115 children) showed improved quality of life measures and work impairment in both groups after at least one year of treatment.
- Despite the treatment's favorable safety profile, including a 66.8% reporting rate of adverse events (most commonly conjunctivitis), there were significant amounts of missing data in reported outcomes, particularly in children.
Article Synopsis
- * Out of 103 patients, significant improvements were observed over 28 weeks, with high rates of reduction in eczema severity and itching.
- * While some patients discontinued due to ineffectiveness or adverse events (mainly nausea), abrocitinib showed effectiveness for those who previously did not respond to other treatments like dupilumab or upadacitinib.
Article Synopsis
- The study examines patient-centred dosing of dupilumab for atopic dermatitis (AD), focusing on its effectiveness and cost savings in daily practice.
- A total of 595 adult patients were assessed, with 401 managing to successfully taper their dupilumab treatment after controlling their eczema symptoms for over a year.
- Successful tapering was achieved in 83.3% of cases, suggesting that reducing medication frequency is both effective for patient health and economically beneficial, with estimated savings of nearly €4 million.
Effectiveness of Upadacitinib in Patients with Atopic Dermatitis including those with Inadequate Response to Dupilumab and/or Baricitinib: Results from the BioDay Registry.
Acta Derm Venereol
February 2023
Article Synopsis
- Upadacitinib, a selective Janus kinase-1 inhibitor, is effective for treating moderate-to-severe atopic dermatitis based on clinical trials, but more studies on its real-world application are needed.
- A prospective study involving 47 patients showed that after 16 weeks of treatment, 73% achieved a significant reduction in eczema severity, and 69% reported lower itch levels.
- While the treatment worked well for patients who had not responded to other medications, about 30% of participants discontinued due to ineffectiveness or side effects, with common issues including acne, herpes, nausea, and respiratory infections.
Article Synopsis
- Clinical trials indicate that baricitinib is an effective oral treatment for moderate-to-severe atopic dermatitis, though there's limited data from everyday clinical use.
- A multicenter study assessed the treatment's effectiveness and safety over 16 weeks in 51 adults, using various outcome measurements at multiple check-ins.
- Despite some positive outcomes, a significant number of patients (43.2%) stopped treatment due to ineffectiveness or side effects, highlighting the variability in effectiveness and safety in this patient group.
Dupilumab Drug Survival and Associated Predictors in Patients With Moderate to Severe Atopic Dermatitis: Long-term Results From the Daily Practice BioDay Registry.
JAMA Dermatol
September 2022
Article Synopsis
- Long-term data on the survival of dupilumab in patients with atopic dermatitis (AD) is limited, and there is a need to understand what factors influence its effectiveness over time.
- The study analyzed data from 715 adult patients in the Netherlands, showing that dupilumab had drug survival rates of 90.3%, 85.9%, and 78.6% at 1, 2, and 3 years, respectively.
- Factors linked to shorter drug survival included the use of immunosuppressants and being a nonresponder at 4 weeks, as well as age over 65 and severe forms of AD, indicating specific characteristics that could predict treatment outcomes.
This study identified risk factors for the development of dupilumab-associated ocular surface disease in patients with moderate-to-severe atopic dermatitis in a large prospective daily practice cohort. Data from the Dutch BioDay Registry were used to assess the risk of developing dupilumab-associated ocular surface disease, by performing univariate and multivariate logistic regression analyses. A total of 469 patients were included, of which 152/469 (32.
View Article and Find Full Text PDFDupilumab treatment improves signs, symptoms, and quality of life in patients with moderate-to-severe atopic dermatitis. This study evaluated the impact of dupilumab treatment on absenteeism, presenteeism, and related costs in a large multi-centre cohort of adult patients with difficult-to-treat atopic dermatitis in daily practice. Patients treated with dupilumab participating in the Dutch BioDay Registry reporting employment were included.
View Article and Find Full Text PDFDupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry.
J Am Acad Dermatol
April 2021
Background: Real-life data on long-term effectiveness and safety of dupilumab in atopic dermatitis patients are limited.
Objective: To study 52-week effectiveness and safety of dupilumab in a prospective multicenter cohort of adult patients with treatment-refractory atopic dermatitis.
Methods: Patients treated with dupilumab and participating in the Dutch BioDay registry were included.
Two-year drug survival of dupilumab in a large cohort of difficult-to-treat adult atopic dermatitis patients compared to cyclosporine A and methotrexate: Results from the BioDay registry.
Allergy
September 2020
In a recent investigation of bone mineral density (BMD) in patients with moderate-to-severe AD, we found that one third of the patients had a low BMD, predominately males. This could be due to the use of topical corticosteroids or due to chronic inflammation. However, neither could be held responsible for the above finding.
View Article and Find Full Text PDFBackground: Cyclosporin A (CsA) is frequently used in the treatment of severe atopic dermatitis (AD). Enteric-coated mycophenolate sodium (EC-MPS) may be an alternative with equal efficacy and fewer side effects.
Objective: The aim of this observer-blinded randomized controlled trial was to compare EC-MPS with CsA as long-term treatment in adult patients with severe AD.
Background: Percutaneous absorption of topically applied 0.05% clobetasol propionate (CLO) can be assessed indirectly by measuring cortisol levels. A direct way is to measure systemic levels of topically applied CLO.
View Article and Find Full Text PDFIntroduction: There is concern about the development of glaucoma and cataracts associated with topical corticosteroid use in patients with atopic dermatitis (AD).
Objective: We evaluated glaucoma and cataract development in patients with AD to determine whether they are associated with the cumulative dose of topical steroids and the use of topical corticosteroids on the eyelids and periorbital region.
Methods: In all, 88 patients with AD were recruited from the University Medical Centre Utrecht.
Background: Low bone mineral density (BMD) has been reported in 30.4% of adult patients with atopic dermatitis (AD).
Objective: The aim of this study was to determine the prevalence of low BMD in children with moderate to severe AD and to investigate the relation between BMD and corticosteroid and cyclosporine therapy.
The Self-Administered Eczema Area and Severity Index (SA-EASI) is one of the few patient based atopic dermatitis (AD) disease activity scores and was found to be highly correlated with the EASI. Correlation with other frequently used scoring methods has not been investigated. The aim of this study was to evaluate the relation of the SA-EASI with two physician-based disease activity scores (objective SCORAD and SASSAD score) and with a serum marker for AD (Thymus and Activation-Regulated Cytokine [TARC]) in children with AD.
View Article and Find Full Text PDF